[The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL). Although this lymphoma is curable, 40% of patients with DLBCL will die of relapsed or refractory disease. 18F-Fluoro-deoxyglucose positron emission tomography (FDG-PET) is a noninvasive, 3-dimensional, functional imaging modality. When combined with the anatomical imaging tool computed tomography (CT), PET/CT can differentiate among others necrotic masses and viable tumors. PET scan has become a basic clinical tool for staging and response assessment in aggressive lymphomas, such as DLBCL. It has been evaluated in pretreatment staging, restaging, monitoring during therapy, post-therapy surveillance and assessment of transformation. Based on the preliminary results of several studies FDG-PET scans play an important role in the early assessment of treatment response, in planning of the treatment including radiation therapy and in the estimation of prognosis.
I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. drpakmel@gmail.com.
Melinda
M
Paksi
I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. drpakmel@gmail.com.
Judit
J
Demeter
Scanomed Orvosi Diagnosztikai Kutató és Oktató Kft., Budapest, Hungary.
Péter
P
Szabó
D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18